- Home
- ARMP vs LFCR Comparison
ARMP vs LFCR Comparison
Compare ARMP & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARMP | LFCR |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.7M | 269.8M |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARMP | LFCR |
|---|---|---|
| Price | $11.56 | $6.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 45.6K | ★ 100.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | $2.80 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $0.90 | $4.76 |
| 52 Week High | $13.75 | $8.98 |
Technical Indicators
Market Signals| Indicator | ARMP | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 31.32 |
| Support Level | $5.14 | $6.60 |
| Resistance Level | $12.23 | $7.03 |
| Average True Range (ATR) | 1.07 | 0.29 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 80.00 | 27.55 |
Price Performance
Historical ComparisonAbout ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.